JPMorgan analyst Jessica Fye raised the firm’s price target on Legend Biotech (LEGN) to $78 from $77 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Appoints Carlos Santos as CFO to Drive Financial Strategy
- Legend Biotech appoints Santos as Chief Financial Officer
- Legend Biotech’s Earnings Call: Growth and Success
- Legend Biotech price target raised to $77 from $75 at RBC Capital
- Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating